AU2007206756B2 - Detecting and predicting pre-eclampsia - Google Patents

Detecting and predicting pre-eclampsia Download PDF

Info

Publication number
AU2007206756B2
AU2007206756B2 AU2007206756A AU2007206756A AU2007206756B2 AU 2007206756 B2 AU2007206756 B2 AU 2007206756B2 AU 2007206756 A AU2007206756 A AU 2007206756A AU 2007206756 A AU2007206756 A AU 2007206756A AU 2007206756 B2 AU2007206756 B2 AU 2007206756B2
Authority
AU
Australia
Prior art keywords
mmp
subject
plgf
determining
pai
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2007206756A
Other languages
English (en)
Other versions
AU2007206756A1 (en
Inventor
Lucilla Poston
Andrew Shennan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Revvity Health Sciences Inc
Original Assignee
Revvity Health Sciences Inc
Revvity Health Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revvity Health Sciences Inc, Revvity Health Sciences Inc filed Critical Revvity Health Sciences Inc
Publication of AU2007206756A1 publication Critical patent/AU2007206756A1/en
Application granted granted Critical
Publication of AU2007206756B2 publication Critical patent/AU2007206756B2/en
Assigned to PERKINELMER HEALTH SCIENCES, INC. reassignment PERKINELMER HEALTH SCIENCES, INC. Request to Amend Deed and Register Assignors: PERKINELMER LAS, INC.
Assigned to Revvity Health Sciences, Inc.. reassignment Revvity Health Sciences, Inc.. Request to Amend Deed and Register Assignors: PERKINELMER HEALTH SCIENCES, INC.
Assigned to REVVITY HEALTH SCIENCES, INC. reassignment REVVITY HEALTH SCIENCES, INC. Request to Amend Deed and Register Assignors: Revvity Health Sciences, Inc..
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Mold Materials And Core Materials (AREA)
  • Optical Fibers, Optical Fiber Cores, And Optical Fiber Bundles (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Holo Graphy (AREA)
AU2007206756A 2006-01-17 2007-01-17 Detecting and predicting pre-eclampsia Active AU2007206756B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0600916.1A GB0600916D0 (en) 2006-01-17 2006-01-17 detecting and predicting pre-eclampsia
GB0600916.1 2006-01-17
PCT/GB2007/000123 WO2007083099A1 (en) 2006-01-17 2007-01-17 Detecting and predicting pre-eclampsia

Publications (2)

Publication Number Publication Date
AU2007206756A1 AU2007206756A1 (en) 2007-07-26
AU2007206756B2 true AU2007206756B2 (en) 2011-06-16

Family

ID=35998177

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007206756A Active AU2007206756B2 (en) 2006-01-17 2007-01-17 Detecting and predicting pre-eclampsia

Country Status (10)

Country Link
US (1) US7638287B2 (enExample)
EP (1) EP1974220B1 (enExample)
JP (1) JP2009524014A (enExample)
AT (1) ATE504002T1 (enExample)
AU (1) AU2007206756B2 (enExample)
CA (1) CA2602681C (enExample)
DE (1) DE602007013524D1 (enExample)
ES (1) ES2364314T3 (enExample)
GB (1) GB0600916D0 (enExample)
WO (1) WO2007083099A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008098734A1 (en) 2007-02-12 2008-08-21 Stefan Hansson Diagnosis and treatment of preeclampsia
GB0715030D0 (en) * 2007-08-02 2007-09-12 Wilson Carol J Testing process
US8647832B2 (en) 2008-01-25 2014-02-11 Perkinelmer Health Sciences, Inc. Methods for determining the risk of prenatal complications
CN102224422A (zh) * 2008-11-20 2011-10-19 珀金埃尔默健康科学公司 使用pigf-2和pigf-3标志物确定先兆子痫风险的方法
WO2010091253A1 (en) 2009-02-06 2010-08-12 Women & Infants' Hospital Of Rhode Island Compositions, formulations and methods of treating preeclampsia-type disorders of pregnancy
AU2011231982B2 (en) * 2010-03-24 2014-02-20 Preelumina Diagnostics Ab HbF and A1M as early stage markers for preeclampsia
WO2013087887A2 (en) * 2011-12-15 2013-06-20 Pronota N.V. Biomarkers and parameters for hypertensive disorders of pregnancy
ES2718905T3 (es) * 2012-04-24 2019-07-05 Siemens Healthcare Diagnostics Inc Métodos de examen de preeclampsia
WO2014124396A1 (en) * 2013-02-08 2014-08-14 University Of Iowa Research Foundation Therapeutic strategies for the treatment of preeclampsia
US10119978B2 (en) * 2013-03-15 2018-11-06 Wallac Oy System and method for determining risk of diabetes based on biochemical marker analysis
EP3189336B1 (en) 2014-09-02 2018-11-07 Wallac OY Method for determining risk of pre-eclampsia
FR3037657B1 (fr) * 2015-06-22 2017-06-23 Univ Rouen Centre Hospitalier Methode de diagnostic des troubles causes par l'alcoolisation foetale
US20200395127A1 (en) * 2017-11-17 2020-12-17 University Of Washington Connected system for information-enhanced test results
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS
GB2620035A (en) * 2021-02-10 2023-12-27 Mirvie Inc Methods and systems for conducting pregnancy-related clinical trials
FR3157091A1 (fr) * 2023-12-26 2025-06-27 Universite De Montpellier Prédiction du comportement biomécanique de la paroi artérielle à travers l’analyse temporelle du signal oscillométrique au cours de la mesure de pression

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002037120A2 (en) * 2000-11-02 2002-05-10 King's College London Diagnosis of pre-eclampsia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5331298A (en) 1996-12-23 1998-07-17 Cambridge University Technical Services Limited Diagnosis and treatment of pathological pregnancies
US7435419B2 (en) * 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
GB0308967D0 (en) * 2003-04-17 2003-05-28 Univ London Screen for pre-eclampsia
US7344892B2 (en) * 2003-09-23 2008-03-18 Beth Israel Deaconess Medical Center, Inc. Screening for gestational disorders
CA2485722A1 (en) * 2003-10-22 2005-04-22 Paul Lehmann Soluble transferrin receptor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002037120A2 (en) * 2000-11-02 2002-05-10 King's College London Diagnosis of pre-eclampsia

Also Published As

Publication number Publication date
ES2364314T8 (es) 2011-09-22
CA2602681A1 (en) 2007-07-26
CA2602681C (en) 2017-03-14
AU2007206756A1 (en) 2007-07-26
US20070178530A1 (en) 2007-08-02
GB0600916D0 (en) 2006-02-22
EP1974220A1 (en) 2008-10-01
JP2009524014A (ja) 2009-06-25
EP1974220B1 (en) 2011-03-30
WO2007083099A1 (en) 2007-07-26
US7638287B2 (en) 2009-12-29
DE602007013524D1 (de) 2011-05-12
ATE504002T1 (de) 2011-04-15
HK1119244A1 (en) 2009-02-27
ES2364314T3 (es) 2011-08-31

Similar Documents

Publication Publication Date Title
AU2007206756B2 (en) Detecting and predicting pre-eclampsia
CA2759534C (en) Method for determining maternal health risks
Khalil et al. First trimester maternal serum placental protein 13 for the prediction of pre‐eclampsia in women with a priori high risk
Odibo et al. First-trimester placental protein 13, PAPP-A, uterine artery Doppler and maternal characteristics in the prediction of pre-eclampsia
EP2368119B1 (en) Method for determining the risk of preeclampsia using pigf-2 and pigf-3 markers
Schneuer et al. Angiopoietin 1 and 2 serum concentrations in first trimester of pregnancy as biomarkers of adverse pregnancy outcomes
EP3189336B1 (en) Method for determining risk of pre-eclampsia
Senapati et al. Predicting first trimester pregnancy outcome: derivation of a multiple marker test
Lyell et al. Prenatal screening, epidemiology, diagnosis, and management of preeclampsia
Yliniemi et al. First trimester placental retinol-binding protein 4 (RBP4) and pregnancy-associated placental protein A (PAPP-A) in the prediction of early-onset severe pre-eclampsia
Kumar et al. Correlation of sFlt/PlGF ratio with severity of preeclampsia in an Indian population
Njoroge et al. The interval between births and the risk of recurrent preeclampsia among predominantly high risk women in urban tertiary care center
Kumar et al. Role of sFLT-1/PlGF ratio in predicting severe adverse materno-fetal outcome in high risk women
Gharib et al. Predictive value of maternal serum C-reactive protein levels with severity of preeclampsia
Tussupkaliyev et al. Urinary placental growth factor determined in the first trimester of pregnancy as a predictor of preeclampsia
HK1119244B (en) Detecting and predicting pre-eclampsia
WO2021009260A1 (en) Method of prognosing and diagnosing preeclampsia
MS EARLY DETECTION OF HELLP SYNDROME USING BIOLOGICAL MARKERS AND DOPPLER ULTRASONOGRAPHY

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: PERKINELMER HEALTH SCIENCES, INC.

Free format text: FORMER NAME(S): PERKINELMER LAS, INC.

HB Alteration of name in register

Owner name: REVVITY HEALTH SCIENCES, INC.

Free format text: FORMER NAME(S): REVVITY HEALTH SCIENCES, INC..

Owner name: REVVITY HEALTH SCIENCES, INC..

Free format text: FORMER NAME(S): PERKINELMER HEALTH SCIENCES, INC.